Lead Product(s) : GBS-NN/NN2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : MinervaX ApS
Deal Size : Undisclosed
Deal Type : Collaboration
MinervaX and Wacker Partner On Group B Strep Vaccine Manufacturing
Details : The collaboration aims to manufacture MinervaX's active protein ingredients of its GBS vaccine, GBS NN, a novel, prophylactic vaccine against Group B Streptococcus.
Product Name : GBS-NN/NN2
Product Type : Vaccine
Upfront Cash : Undisclosed
September 17, 2024
Lead Product(s) : GBS-NN/NN2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : MinervaX ApS
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ifx-1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
Product Name : Ifx-1
Product Type : Antibody
Upfront Cash : Inapplicable
March 31, 2022
Lead Product(s) : Ifx-1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : COMIRNATY is a vaccine indicated for active immunization to prevent coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 in Children 5 to under 12. Years of Age.
Product Name : Comirnaty
Product Type : Vaccine
Upfront Cash : Inapplicable
November 25, 2021
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine for adult, now got emergency use authorization for children 5 through 11 years of age based on safety, tolerability and immunogenicity data.
Product Name : Comirnaty
Product Type : Vaccine
Upfront Cash : Inapplicable
October 29, 2021
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifx-1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : German Federal Government
Deal Size : $50.7 million
Deal Type : Funding
Details : The purpose of the grant is to advance clinical development activities in COVID-19 and to secure manufacturing capacity for vilobelimab in Germany and support the development of vilobelimab for the treatment of severely ill, mechanically ventilated COVID...
Product Name : Ifx-1
Product Type : Antibody
Upfront Cash : Undisclosed
October 19, 2021
Lead Product(s) : Ifx-1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : German Federal Government
Deal Size : $50.7 million
Deal Type : Funding
Lead Product(s) : Alteplase
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer Ingelheim Focus Covid-19 Therapy Research on Development of Alteplase
Details : It evaluated efficacy and safety of two different dosing regimens of intravenous alteplase given for up to 5 days on top of best available medical management (standard of care (SOC)), compared with SOC alone.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
July 26, 2021
Lead Product(s) : Alteplase
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CVnCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CureVac Final Data from Phase 2b/3 Trial of CVnCoV, Demonstrates Protection in Age Group of 18 to 60
Details : The data confirm the favorable safety profile of CVnCoV in all age groups. The study will continue to complete follow-up analyses for trial participants. Available data have been communicated to the European Medicines Agency (EMA).
Product Name : CVnCoV
Product Type : Vaccine
Upfront Cash : Inapplicable
June 30, 2021
Lead Product(s) : CVnCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CVnCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
Details : CureVac has reported second interim analysis results from the global Phase IIb/III HERALD study, where its Covid-19 vaccine candidate, CVnCoV, failed to meet prespecified statistical success criteria.
Product Name : CVnCoV
Product Type : Vaccine
Upfront Cash : Inapplicable
June 16, 2021
Lead Product(s) : CVnCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CVnCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : GSK
Deal Size : $180.0 million
Deal Type : Collaboration
GSK and CureVac To Develop Next Generation mRNA COVID-19 Vaccines
Details : Companies aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use. GSK will support manufacture of up to 100 million doses of CureVac’s first generation COVID-19 vaccine CVnCoV in 2021.
Product Name : CVnCoV
Product Type : Vaccine
Upfront Cash : Undisclosed
March 02, 2021
Lead Product(s) : CVnCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : GSK
Deal Size : $180.0 million
Deal Type : Collaboration
Lead Product(s) : CVnCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoV
Details : CureVac has enrolled the first participant in the pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The Phase 2b/3 trial called HERALD will assess the safety and efficacy of CVnCoV in adults at a dose of 12 µg.
Product Name : CVnCoV
Product Type : Vaccine
Upfront Cash : Inapplicable
December 14, 2020
Lead Product(s) : CVnCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable